Navepegritide
Brand names: Yuviwel · Active ingredient: Navepegritide
In short: YUVIWEL® is indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses. This indication is approved under accelerated approval based on an improvement in annualized growth velocity .
What is Navepegritide used for?
YUVIWEL® is indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses. This indication is approved under accelerated approval based on an improvement in annualized growth velocity . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Navepegritide dosage
The recommended once-weekly dosage of YUVIWEL is based on the patient´s body weight .
YUVIWEL is administered by subcutaneous injection. YUVIWEL must be reconstituted prior to use .
Patient Body weight | Weekly Dose | Injection Volume | Vial Strength for ReconstitutionThe concentration of navepegritide is 2.2 mg/mL in a reconstituted 1.3 mg vial; 4.6 mg/mL in a reconstituted 2.8 mg vial; and 5.5 mg/mL in a reconstituted 5.5 mg vial.
8 to 9.9 kg | 0.88 mg | 0.4 mL | 1.3 mg
10 to 13.4 kg | 1.2 mg | 0.55 mL
13.5 to 17.5 kg | 1.6 mg | 0.35 mL | 2.8 mg
17.6 to 23 kg | 2.1 mg | 0.45 mL
23.1 to 30.5 kg | 2.8 mg | 0.6 mL
30.6 to 41.2 kg | 3.6 mg | 0.65 mL | 5.5 mg
41.3 to 55.9 kg | 5 mg | 0.9 mL
56 to 73.5 kg | 6.6 mg | 1.2 mL (use 2 Kits) Administer 0.6 mL from each Kit
73.6 to 90 kg | 8.8 mg | 1.6 mL (use 2 Kits) Administer 0.8 mL from each Kit
Switching from Daily C-type Natriuretic Peptide (CNP) Analog
Start once-weekly YUVIWEL on the day after completing the last dose of daily CNP therapy.
Periodically monitor the patient's growth and adjust the dosage according to the actual body weight . Discontinue YUVIWEL upon confirmation of no further growth potential, indicated by closure of the epiphyses.
Patients and caregivers who will administer YUVIWEL should receive appropriate training by a healthcare provider prior to use. Refer to the Instructions for Use for complete preparation and administration instructions with illustrations.
Before administration, reconstitute YUVIWEL using the provided prefilled diluent syringe containing Sterile Water for Injection as described below.
Needles and syringes supplied with YUVIWEL are for single use only.
If the product was refrigerated, allow the YUVIWEL vial and the prefilled diluent syringe to reach room temperature (about 30 minutes) before reconstitution.
Screw a preparation needle onto the prefilled diluent syringe and inject the entire diluent volume into the vial. Shake the vial up and down for 15 seconds. Do not swirl or roll. The reconstituted YUVIWEL vial should stand at room temperature for 5 minutes after shaking. Dispose the diluent syringe with attached preparation needle immediately after injecting the diluent into the vial.
YUVIWEL should be visually inspected for particles or discoloration prior to administration, whenever solution and container permit. Once reconstituted, YUVIWEL is a clear and colorless solution. Do not use the solution if it is discolored, cloudy or contains visible particles. Air bubbles may be seen, and this is normal.
Screw a new preparation needle onto the injection syringe and withdraw the prescribed injection volume from the reconstituted vial. …
How to take Navepegritide — instructions & advice from the label
Advise the patient and/or caregiver to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
Administration Instructions
Provide appropriate instructions for injection to the patient/caregiver based on the YUVIWEL Instructions for Use (available at www.Yuviwel.com). Patients/caregivers and healthcare providers may also call the Ascendis Pharma Customer Support toll-free number at 1-844-442-7236 (1-844-44ASCENDIS) for assistance or additional training, if needed.
Advise patients/caregivers to refer to the Instructions for Use that accompanies YUVIWEL for complete reconstitution and administration instructions with illustrations .
Advise patients/caregivers to administer YUVIWEL once weekly on the dosing day, at any time of day.
Advise patients and caregivers to rotate the site of injection to reduce the risk of injection site reactions .
Missed Dose
Advise patients/caregivers that to avoid missed doses, YUVIWEL can be taken up to 2 days before or 2 days after the scheduled dosing day. …
Warnings & precautions
Do not take this medicine if: None.
Transient decreases in blood pressure have been reported with a once daily CNP analog. Subjects with hemodynamically significant cardiovascular disease were excluded from participation in navepegritide clinical trials. Advise patients to contact their healthcare provider if they experience symptoms of decreased blood pressure (e.g., dizziness, fatigue and/or nausea) while being treated with YUVIWEL.
Navepegritide side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of YUVIWEL was evaluated in pediatric patients with achondroplasia in two randomized, placebo-controlled trials of navepegritide. Trial 1 included a 52-week, randomized, double-blind, placebo-controlled period, followed by a 52-week, single-arm, open-label extension (OLE) period. In Trial 1, 84 pediatric participants with achondroplasia (mean age 5.7 years; range: 2 to 12 years) were randomized to subcutaneous navepegritide 0.1 mg/kg/week (n = 57) or placebo (n = 27) . Trial 2 included a randomized, double-blind, placebo-controlled dose-finding period. In Trial 2, 57 pediatric participants with achondroplasia (mean age 5.9 years; range: 2 to 10 years) were randomized 3:1 to subcutaneous navepegritide 0.006, 0.02, 0.05, or 0.1 mg/kg or placebo for 52 weeks. At Week 52, all participants transitioned to an OLE period during which they received navepegritide 0.1 mg/kg/week for 104 weeks.
The adverse reaction rates for navepegritide were derived from pediatric participants with achondroplasia who received navepegritide 0.1 mg/kg/week or placebo during the double-blind period of Trials 1 and 2. …
About this medicine
YUVIWEL for injection contains navepegritide, a C-type natriuretic peptide (CNP) analog. Navepegritide is a prodrug of active CNP consisting of a CNP moiety transiently conjugated to two branched 20 kDa methoxy polyethylene glycol (mPEG) moieties via a proprietary TransCon® Linker. The amino acid sequence of the CNP moiety is identical to the 38 amino acid sequence of residues 89-126 of human CNP. The structural formula of navepegritide is as follows:
The molecular formula is C231H386N64O67S5 + 4 × (C2H4O)n, where n is between 200 and 250. The average molecular weight is approximately 45 kDa.
YUVIWEL is provided as a sterile, lyophilized white to off-white powder for reconstitution to a colorless solution with Sterile Water for Injection, USP (diluent). The diluent for reconstitution of YUVIWEL is provided in a prefilled syringe.
The compositions of YUVIWEL are shown in Table 3.
Strength | Composition of YUVIWEL (gross content per vial)An overfill is included in the vial to compensate for loss in the vial and during transfer. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID e01c1197-338f-414c-b804-808e129ebc8c. Read the full official label on DailyMed.